Evaluation of blood glucose levels after hepatitis B immune globulin administration utilizing two different blood glucose monitoring systems

K. Shetty, T. Lukose, R. S. Brown

Research output: Contribution to journalArticle

Abstract

Background Hepatitis B Immune Globulin (HBIG) is used post liver transplantation (OLT) in hepatitis B surface antigen-positive recipients to prevent recurrence of hepatitis B. One formulation of HBIG, HepaGam B, contains the disaccharide maltose, which can potentially falsely elevate glucose readings when glucose nonspecific point of care (GNSPOC) testing is used, such as a glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ)-based method. This can result in inappropriate administration of antidiabetic agents and resultant episodes of clinically significant hypoglycemia. Glucose specific point of care (GSPOC) testing, such as a glucose oxidase-based method, however, is not affected by the presence of maltose. The purpose of this study was to determine if there was a significant difference in glucose readings using GSPOC and GNSPOC monitoring devices after HBIG administration. Methods This is a nonrandomized, prospective study evaluating patients receiving maintenance HBIG therapy over 3 months post liver transplantation. Blood glucose levels in each subject were analyzed by GSPOC and GNSPOC devices at specific times around HBIG administration. Results Five adult OLT recipients receiving maintenance HBIG therapy were administered HepaGam B during the regularly scheduled outpatient visits. The median difference (GNSPOC minus GSPOC) predose as well as immediately, 60 minutes, and 120 minutes postdose were: -2, 11, 6, and 0 mg/dL, respectively. A random intercept model was used to fit the five subjects' glucose reading data over time. The Meter by Time interaction effect was not significant (P = .59) and the Meter effect was not significant (P = .46), which demonstrated no statistical difference between GNS and GS readings following HBIG administration. Conclusions Based on these results, there is not a significant difference between GSPOC and GNSPOC readings after administration of this HBIG formulation.

Original languageEnglish (US)
Pages (from-to)4123-4126
Number of pages4
JournalTransplantation Proceedings
Volume42
Issue number10
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Hepatitis B
Point-of-Care Systems
Blood Glucose
Immunoglobulins
Glucose
Reading
Maltose
Liver Transplantation
Maintenance
Glucose 1-Dehydrogenase
Equipment and Supplies
Glucose Oxidase
Disaccharides
Hepatitis B Surface Antigens
Hypoglycemia
Hypoglycemic Agents
Outpatients
Prospective Studies

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Evaluation of blood glucose levels after hepatitis B immune globulin administration utilizing two different blood glucose monitoring systems. / Shetty, K.; Lukose, T.; Brown, R. S.

In: Transplantation Proceedings, Vol. 42, No. 10, 12.2010, p. 4123-4126.

Research output: Contribution to journalArticle

@article{61b57ebe4e1240f783433a84fafe3d88,
title = "Evaluation of blood glucose levels after hepatitis B immune globulin administration utilizing two different blood glucose monitoring systems",
abstract = "Background Hepatitis B Immune Globulin (HBIG) is used post liver transplantation (OLT) in hepatitis B surface antigen-positive recipients to prevent recurrence of hepatitis B. One formulation of HBIG, HepaGam B, contains the disaccharide maltose, which can potentially falsely elevate glucose readings when glucose nonspecific point of care (GNSPOC) testing is used, such as a glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ)-based method. This can result in inappropriate administration of antidiabetic agents and resultant episodes of clinically significant hypoglycemia. Glucose specific point of care (GSPOC) testing, such as a glucose oxidase-based method, however, is not affected by the presence of maltose. The purpose of this study was to determine if there was a significant difference in glucose readings using GSPOC and GNSPOC monitoring devices after HBIG administration. Methods This is a nonrandomized, prospective study evaluating patients receiving maintenance HBIG therapy over 3 months post liver transplantation. Blood glucose levels in each subject were analyzed by GSPOC and GNSPOC devices at specific times around HBIG administration. Results Five adult OLT recipients receiving maintenance HBIG therapy were administered HepaGam B during the regularly scheduled outpatient visits. The median difference (GNSPOC minus GSPOC) predose as well as immediately, 60 minutes, and 120 minutes postdose were: -2, 11, 6, and 0 mg/dL, respectively. A random intercept model was used to fit the five subjects' glucose reading data over time. The Meter by Time interaction effect was not significant (P = .59) and the Meter effect was not significant (P = .46), which demonstrated no statistical difference between GNS and GS readings following HBIG administration. Conclusions Based on these results, there is not a significant difference between GSPOC and GNSPOC readings after administration of this HBIG formulation.",
author = "K. Shetty and T. Lukose and Brown, {R. S.}",
year = "2010",
month = "12",
doi = "10.1016/j.transproceed.2010.09.131",
language = "English (US)",
volume = "42",
pages = "4123--4126",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Evaluation of blood glucose levels after hepatitis B immune globulin administration utilizing two different blood glucose monitoring systems

AU - Shetty, K.

AU - Lukose, T.

AU - Brown, R. S.

PY - 2010/12

Y1 - 2010/12

N2 - Background Hepatitis B Immune Globulin (HBIG) is used post liver transplantation (OLT) in hepatitis B surface antigen-positive recipients to prevent recurrence of hepatitis B. One formulation of HBIG, HepaGam B, contains the disaccharide maltose, which can potentially falsely elevate glucose readings when glucose nonspecific point of care (GNSPOC) testing is used, such as a glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ)-based method. This can result in inappropriate administration of antidiabetic agents and resultant episodes of clinically significant hypoglycemia. Glucose specific point of care (GSPOC) testing, such as a glucose oxidase-based method, however, is not affected by the presence of maltose. The purpose of this study was to determine if there was a significant difference in glucose readings using GSPOC and GNSPOC monitoring devices after HBIG administration. Methods This is a nonrandomized, prospective study evaluating patients receiving maintenance HBIG therapy over 3 months post liver transplantation. Blood glucose levels in each subject were analyzed by GSPOC and GNSPOC devices at specific times around HBIG administration. Results Five adult OLT recipients receiving maintenance HBIG therapy were administered HepaGam B during the regularly scheduled outpatient visits. The median difference (GNSPOC minus GSPOC) predose as well as immediately, 60 minutes, and 120 minutes postdose were: -2, 11, 6, and 0 mg/dL, respectively. A random intercept model was used to fit the five subjects' glucose reading data over time. The Meter by Time interaction effect was not significant (P = .59) and the Meter effect was not significant (P = .46), which demonstrated no statistical difference between GNS and GS readings following HBIG administration. Conclusions Based on these results, there is not a significant difference between GSPOC and GNSPOC readings after administration of this HBIG formulation.

AB - Background Hepatitis B Immune Globulin (HBIG) is used post liver transplantation (OLT) in hepatitis B surface antigen-positive recipients to prevent recurrence of hepatitis B. One formulation of HBIG, HepaGam B, contains the disaccharide maltose, which can potentially falsely elevate glucose readings when glucose nonspecific point of care (GNSPOC) testing is used, such as a glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ)-based method. This can result in inappropriate administration of antidiabetic agents and resultant episodes of clinically significant hypoglycemia. Glucose specific point of care (GSPOC) testing, such as a glucose oxidase-based method, however, is not affected by the presence of maltose. The purpose of this study was to determine if there was a significant difference in glucose readings using GSPOC and GNSPOC monitoring devices after HBIG administration. Methods This is a nonrandomized, prospective study evaluating patients receiving maintenance HBIG therapy over 3 months post liver transplantation. Blood glucose levels in each subject were analyzed by GSPOC and GNSPOC devices at specific times around HBIG administration. Results Five adult OLT recipients receiving maintenance HBIG therapy were administered HepaGam B during the regularly scheduled outpatient visits. The median difference (GNSPOC minus GSPOC) predose as well as immediately, 60 minutes, and 120 minutes postdose were: -2, 11, 6, and 0 mg/dL, respectively. A random intercept model was used to fit the five subjects' glucose reading data over time. The Meter by Time interaction effect was not significant (P = .59) and the Meter effect was not significant (P = .46), which demonstrated no statistical difference between GNS and GS readings following HBIG administration. Conclusions Based on these results, there is not a significant difference between GSPOC and GNSPOC readings after administration of this HBIG formulation.

UR - http://www.scopus.com/inward/record.url?scp=78650454574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650454574&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2010.09.131

DO - 10.1016/j.transproceed.2010.09.131

M3 - Article

C2 - 21168642

AN - SCOPUS:78650454574

VL - 42

SP - 4123

EP - 4126

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 10

ER -